product name FPH1 (BRD-6125)
Description: FPH1 (also known as BRD-6125) is a small molecule that promotes expansion of iPS-derived hepatocytes. FPH1 belongs to the functional proliferation hits which are screened out by their ability to permit renewable sourcing of functional human hepatocytes. This ability of FPH1 is not dependent on the donors of the hepatocytes. It has been found that FPH1 was active against the primary human hepatocytes from six cell sources of genetically diverse individuals. Besides that, FPH1 can affect the hepatocyte functions with promoting albumin secretion during the differentiation of iPS cells into iHeps. Moreover, treatment of FPH1 also resulted in the increase of CYP3A4 levels and the decrease of AFP secretion.
References: Nat Chem Biol. 2013 Aug;9(8):514-20.
388.82
Formula
C16H15ClF2N2O3S
CAS No.
708219-39-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 78 mg/mL (200.6 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: FPH1 induces functional proliferation of hepatocytes in vitro, and causes more pronounced hepatocyte morphologies, including polygonal cell shapes, visible nuclei, and more noticeable bile cannaliculi between hepatocytes. Kinase Assay: Cell Assay: FPH1 belongs to the functional proliferation hits which are screened out by their ability to permit renewable sourcing of functional human hepatocytes. This ability of FPH1 is not dependent on the donors of the hepatocytes. It has been found that FPH1 was active against the primary human hepatocytes from six cell sources of genetically diverse individuals. Besides that, FPH1 can affect the hepatocyte functions with promoting albumin secretion during the differentiation of iPS cells into iHeps. Moreover, treatment of FPH1 also resulted in the increase of CYP3A4 levels and the decrease of AFP secretion. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Nat Chem Biol. 2013 Aug;9(8):514-20. |
